PMS-VERAPAMIL SR TABLET (EXTENDED-RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
25-08-2020
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
VERAPAMIL HYDROCHLORIDE
Inapatikana kutoka:
PHARMASCIENCE INC
ATC kanuni:
C08DA01
INN (Jina la Kimataifa):
VERAPAMIL
Kipimo:
240MG
Dawa fomu:
TABLET (EXTENDED-RELEASE)
Tungo:
VERAPAMIL HYDROCHLORIDE 240MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Eneo la matibabu:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0113846003; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
1998-04-23
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
PMS-VERAPAMIL SR
Verapamil hydrochloride Sustained-Release Tablets, USP
240 mg
ANTIHYPERTENSIVE AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
August 25, 2020
Submission Control No.: 241056
_ _
_pms-VERAPAMIL SR Product Monograph _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
................................................................................27
PHARMACEUTICAL INFORMATION
..........................................................................27
CLINICAL TRIALS
..........................................................................................................28
DETAILED PHARMACOLOGY
...........
Soma hati kamili
